STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis

Christian Kosan; Torsten Ginter; Thorsten Heinzel; Oliver H Krämer

doi:10.4161/jkst.26102

STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis

JAKSTAT. 2013 Oct 1;2(4):e26102. doi: 10.4161/jkst.26102. Epub 2013 Aug 19.

Authors

Christian Kosan¹, Torsten Ginter¹, Thorsten Heinzel¹, Oliver H Krämer²

Affiliations

¹ Center for Molecular Biomedicine (CMB); Institute of Biochemistry and Biophysics; University of Jena; Jena, Germany.
² Center for Molecular Biomedicine (CMB); Institute of Biochemistry and Biophysics; University of Jena; Jena, Germany ; Institute of Toxicology; Medical Center of the University Mainz; Mainz, Germany.

Abstract

The cytokine-inducible transcription factors signal transducer and activator of transcription 5A and 5B (STAT5A and STAT5B) are important for the proper development of multicellular eukaryotes. Disturbed signaling cascades evoking uncontrolled expression of STAT5 target genes are associated with cancer and immunological failure. Here, we summarize how STAT5 acetylation is integrated into posttranslational modification networks within cells. Moreover, we focus on how inhibitors of deacetylases and tyrosine kinases can correct leukemogenic signaling nodes involving STAT5. Such small molecules can be exploited in the fight against neoplastic diseases and immunological disorders.

Keywords: HAT; HDAC; HDACi; SIAH; STAT; STAT5; UBCH8; acetylation; cancer; leukemia.

Publication types

Review